Stock Track | Tarsus Pharmaceuticals Soars 6.15% After-Hours on Strong Q4 Revenue Beat and XDEMVY Sales Growth

Stock Track

Feb 24

Tarsus Pharmaceuticals, Inc. (TARS) saw its stock price soar 6.15% in after-hours trading on Monday. The significant upward movement followed the release of the company's fourth-quarter and full-year 2025 financial results.

The biopharmaceutical company reported Q4 revenue of $151.668 million, surpassing analyst estimates of $144.6 million. Full-year net product sales for its flagship drug XDEMVY reached $451.4 million, representing growth of more than 150% year-over-year. Additionally, the company reiterated the peak sales potential for XDEMVY at over $2 billion and provided updates on clinical progress for other pipeline candidates, including the initiation of a Phase 2 trial for TP-04 in ocular rosacea.

Investor sentiment was further bolstered by the company's improved financial performance, with Q4 net loss narrowing to $8.4 million compared to $23.1 million in the same period last year. The company ended 2025 with a strong cash position of $417.3 million in cash, cash equivalents and marketable securities.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1149991908"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1149991908\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1149991908?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-24 05:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1149991908","market":"sg","top_or_hot":-1,"title":"Stock Track | Tarsus Pharmaceuticals Soars 6.15% After-Hours on Strong Q4 Revenue Beat and XDEMVY Sales Growth","media":"Stock Track","content":"<p>Tarsus Pharmaceuticals, Inc. (TARS) saw its stock price soar 6.15% in after-hours trading on Monday. The significant upward movement followed the release of the company's fourth-quarter and full-year 2025 financial results.</p><p>The biopharmaceutical company reported Q4 revenue of $151.668 million, surpassing analyst estimates of $144.6 million. Full-year net product sales for its flagship drug XDEMVY reached $451.4 million, representing growth of more than 150% year-over-year. Additionally, the company reiterated the peak sales potential for XDEMVY at over $2 billion and provided updates on clinical progress for other pipeline candidates, including the initiation of a Phase 2 trial for TP-04 in ocular rosacea.</p><p>Investor sentiment was further bolstered by the company's improved financial performance, with Q4 net loss narrowing to $8.4 million compared to $23.1 million in the same period last year. The company ended 2025 with a strong cash position of $417.3 million in cash, cash equivalents and marketable securities.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Tarsus Pharmaceuticals Soars 6.15% After-Hours on Strong Q4 Revenue Beat and XDEMVY Sales Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Tarsus Pharmaceuticals Soars 6.15% After-Hours on Strong Q4 Revenue Beat and XDEMVY Sales Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-24 05:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Tarsus Pharmaceuticals, Inc. (TARS) saw its stock price soar 6.15% in after-hours trading on Monday. The significant upward movement followed the release of the company's fourth-quarter and full-year 2025 financial results.</p><p>The biopharmaceutical company reported Q4 revenue of $151.668 million, surpassing analyst estimates of $144.6 million. Full-year net product sales for its flagship drug XDEMVY reached $451.4 million, representing growth of more than 150% year-over-year. Additionally, the company reiterated the peak sales potential for XDEMVY at over $2 billion and provided updates on clinical progress for other pipeline candidates, including the initiation of a Phase 2 trial for TP-04 in ocular rosacea.</p><p>Investor sentiment was further bolstered by the company's improved financial performance, with Q4 net loss narrowing to $8.4 million compared to $23.1 million in the same period last year. The company ended 2025 with a strong cash position of $417.3 million in cash, cash equivalents and marketable securities.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TARS","symbol_name":"Tarsus Pharmaceuticals, Inc.","start_time":0,"source_url":"","article_id":"1149991908","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1149991908","pubTimestamp":1771882860,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Tarsus Pharmaceuticals, Inc. (TARS) saw its stock price soar 6.15% in after-hours trading on Monday. The significant upward movement followed the release of the company's fourth-quarter and full-year...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TARS":"Tarsus Pharmaceuticals, Inc."},"translate_title":"股票追踪|Tarsus Pharmaceuticals盘后飙升6.15%，因第四季度营收强劲增长和XDEMVY销售增长","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TARS":1},"content_text":"Tarsus Pharmaceuticals, Inc. (TARS) saw its stock price soar 6.15% in after-hours trading on Monday. The significant upward movement followed the release of the company's fourth-quarter and full-year 2025 financial results.The biopharmaceutical company reported Q4 revenue of $151.668 million, surpassing analyst estimates of $144.6 million. Full-year net product sales for its flagship drug XDEMVY reached $451.4 million, representing growth of more than 150% year-over-year. Additionally, the company reiterated the peak sales potential for XDEMVY at over $2 billion and provided updates on clinical progress for other pipeline candidates, including the initiation of a Phase 2 trial for TP-04 in ocular rosacea.Investor sentiment was further bolstered by the company's improved financial performance, with Q4 net loss narrowing to $8.4 million compared to $23.1 million in the same period last year. The company ended 2025 with a strong cash position of $417.3 million in cash, cash equivalents and marketable securities.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}